Literature DB >> 15743786

Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization.

Maria Letizia Motti1, Daniela Califano, Giancarlo Troncone, Carmela De Marco, Ilenia Migliaccio, Emiliano Palmieri, Luciano Pezzullo, Lucio Palombini, Alfredo Fusco, Giuseppe Viglietto.   

Abstract

Functional inactivation of the tumor suppressor p27(kip1) in human cancer occurs either through loss of expression or through phosphorylation-dependent cytoplasmic sequestration. Here we demonstrate that dysregulation of the PI3K/AKT pathway is important in thyroid carcinogenesis and that p27(kip1) is a key target of the growth-regulatory activity exerted by this pathway in thyroid cancer cells. Using specific PI3K inhibitors (LY294002, wortmannin, and PTEN) and a dominant active AKT construct (myrAKT), we demonstrated that the PI3K/AKT pathway controlled thyroid cell proliferation by regulating the expression and subcellular localization of p27. Results obtained with phospho-specific antibodies and with transfection of nonphosphorylable p27(kip1) mutant constructs demonstrated that PI3K/AKT-dependent regulation of p27(kip1) mislocalization in thyroid cancer cells occurred via phosphorylation of p27(kip1) at T157 and T198 (but not at S10 or T187). Finally, we evaluated whether these results were applicable to human tumors. Analysis of 100 thyroid carcinomas indicated that p27(kip1) phosphorylation at T157/T198 and cytoplasmic mislocalization were preferentially associated with activation of the PI3K/AKT pathway. Thus the PI3/AKT pathway and its effector p27(kip1) play major roles in thyroid carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15743786      PMCID: PMC1602368          DOI: 10.1016/S0002-9440(10)62295-X

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  61 in total

1.  AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1.

Authors:  R H Medema; G J Kops; J L Bos; B M Burgering
Journal:  Nature       Date:  2000-04-13       Impact factor: 49.962

Review 2.  Are p27 and p21 cytoplasmic oncoproteins?

Authors:  Mikhail V Blagosklonny
Journal:  Cell Cycle       Date:  2002 Nov-Dec       Impact factor: 4.534

3.  Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.

Authors:  Hiroyuki Namba; Masahiro Nakashima; Tomayoshi Hayashi; Naomi Hayashida; Shigeto Maeda; Tatiana I Rogounovitch; Akira Ohtsuru; Vladimir A Saenko; Takashi Kanematsu; Shunichi Yamashita
Journal:  J Clin Endocrinol Metab       Date:  2003-09       Impact factor: 5.958

4.  Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer.

Authors:  Giuseppe Viglietto; Maria Letizia Motti; Paola Bruni; Rosa Marina Melillo; Amelia D'Alessio; Daniela Califano; Floriana Vinci; Gennaro Chiappetta; Philip Tsichlis; Alfonso Bellacosa; Alfredo Fusco; Massimo Santoro
Journal:  Nat Med       Date:  2002-09-16       Impact factor: 53.440

5.  Reciprocal control of Forkhead box O 3a and c-Myc via the phosphatidylinositol 3-kinase pathway coordinately regulates p27Kip1 levels.

Authors:  Vidyalakshmi Chandramohan; Sébastien Jeay; Stefania Pianetti; Gail E Sonenshein
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

6.  RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

Authors:  Marina N Nikiforova; Roy A Lynch; Paul W Biddinger; Erik K Alexander; Gerald W Dorn; Giovanni Tallini; Todd G Kroll; Yuri E Nikiforov
Journal:  J Clin Endocrinol Metab       Date:  2003-05       Impact factor: 5.958

7.  BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.

Authors:  Paula Soares; Vítor Trovisco; Ana Sofia Rocha; Jorge Lima; Patrícia Castro; Ana Preto; Valdemar Máximo; Tiago Botelho; Raquel Seruca; Manuel Sobrinho-Simões
Journal:  Oncogene       Date:  2003-07-17       Impact factor: 9.867

8.  BRAF mutation in papillary thyroid carcinoma.

Authors:  Yoram Cohen; Mingzhao Xing; Elizabeth Mambo; Zhongmin Guo; Guogun Wu; Barry Trink; Uziel Beller; William H Westra; Paul W Ladenson; David Sidransky
Journal:  J Natl Cancer Inst       Date:  2003-04-16       Impact factor: 13.506

Review 9.  Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization.

Authors:  Giuseppe Viglietto; Maria Letizia Motti; Alfredo Fusco
Journal:  Cell Cycle       Date:  2002 Nov-Dec       Impact factor: 4.534

10.  Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer.

Authors:  V Vasko; M Saji; E Hardy; M Kruhlak; A Larin; V Savchenko; M Miyakawa; O Isozaki; H Murakami; T Tsushima; K D Burman; C De Micco; M D Ringel
Journal:  J Med Genet       Date:  2004-03       Impact factor: 6.318

View more
  37 in total

1.  AKT1 induces caspase-mediated cleavage of the CDK inhibitor p27Kip1 during cell cycle progression in leukemia cells transformed by FLT3-ITD.

Authors:  Xinping Yang; Suiyang Liu; Surender Kharbanda; Richard M Stone
Journal:  Leuk Res       Date:  2011-12-03       Impact factor: 3.156

2.  Silencing of Dicer1 temporally separates pro- and anti-apoptotic signaling and confers susceptibility to chemotherapy in p53 mutated cells.

Authors:  Tatyana S Nekova; Susanne Kneitz; Hermann Einsele; Gernot Stuhler
Journal:  Cell Cycle       Date:  2014-05-20       Impact factor: 4.534

3.  C-terminal phosphorylation controls the stability and function of p27kip1.

Authors:  Uta Kossatz; Jörg Vervoorts; Irina Nickeleit; Holly A Sundberg; J Simon C Arthur; Michael P Manns; Nisar P Malek
Journal:  EMBO J       Date:  2006-10-19       Impact factor: 11.598

4.  1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells.

Authors:  Linara S Axanova; Yong Q Chen; Thomas McCoy; Guangchao Sui; Scott D Cramer
Journal:  Prostate       Date:  2010-11-01       Impact factor: 4.104

5.  Rewiring of the apoptotic TGF-β-SMAD/NFκB pathway through an oncogenic function of p27 in human papillary thyroid cancer.

Authors:  A R Garcia-Rendueles; J S Rodrigues; M E R Garcia-Rendueles; M Suarez-Fariña; S Perez-Romero; F Barreiro; I Bernabeu; J Rodriguez-Garcia; L Fugazzola; T Sakai; F Liu; J Cameselle-Teijeiro; S B Bravo; C V Alvarez
Journal:  Oncogene       Date:  2016-07-25       Impact factor: 9.867

6.  Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma.

Authors:  Dana-Lynn T Koomoa; Lisette P Yco; Tamas Borsics; Christopher J Wallick; André S Bachmann
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

Review 7.  PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.

Authors:  Zahra Nozhat; Mehdi Hedayati
Journal:  Mol Diagn Ther       Date:  2016-02       Impact factor: 4.074

8.  BRAF (V600E) associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma.

Authors:  Anna Guerra; Vincenzo Marotta; Maurilio Deandrea; Manuela Motta; Paolo Piero Limone; Alessia Caleo; Pio Zeppa; Silvano Esposito; Franco Fulciniti; Mario Vitale
Journal:  Endocrine       Date:  2012-12-01       Impact factor: 3.633

9.  Protein kinase A-independent inhibition of proliferation and induction of apoptosis in human thyroid cancer cells by 8-Cl-adenosine.

Authors:  Audrey J Robinson-White; Hui-Pin Hsiao; Wolfgang W Leitner; Elizabeth Greene; Andrew Bauer; Nancy L Krett; Maria Nesterova; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2007-12-11       Impact factor: 5.958

Review 10.  The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.

Authors:  Motoyasu Saji; Matthew D Ringel
Journal:  Mol Cell Endocrinol       Date:  2009-11-06       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.